Daily Highlights

Recombinant Factor VIII Fc Fusion Protein Inhibits Inflammatory Osteoclast Formation in vitro

Hemophilia is a rare, X-linked recessive inherited bleeding disorder characterized by deficiency of coagulation factor VIII or factor IX activity. It has been associated with low bone mineral density (BMD) potentially due to predisposing factors that include physical inactivity caused by hemophilic arthropathy, vitamin D deficiency and other comorbidities such as HCV/HIV infection.

Read More

Surgical Experience from Four Phase III Studies (HAVEN 1-4) of Emicizumab in Persons with Haemophilia A (PwHA) With or Without FVIII Inhibitors

Emicizumab is a novel, subcutaneously (SC) administered, recombinant, humanized, bispecific monoclonal antibody approved for the prevention of bleeds in persons with hemophilia A (PwHA). Emicizumab restores the function of activated coagulation FVIII, which is deficient in PwHA, by bridging activated FIX and FX to enable effective hemostasis.

Read More